Unrelated Cord Blood Transplant (UCBt) Is Associated Low Rates of Longterm, Persistent Graft Versus Host Disease (GVHD)  by Craddock, J.A. et al.
S230 Oral Presentationsdisease (score 3, 4 or 5). Type of donor: Related: 8pts (siblings: 5pts
and other related:3pts), Unrelated: 28pts. Source of stem cells: bone
marrow (BM): 12pts and umbilical cord blood (UCB):24pts (com-
patibility 6 / 6: 2pts, 5 / 6: 16pts, 4 / 6: 6pts). Conditioning: Cyclo-
phosphamide120-200mg/kg + Oral Busulfan16-20mg/kg +/- rATG.
Most pts received cyclosporine andmethotrexate as GVHDprophy-
laxis.
Results: 28pts is alive and well between 6 months and 17 ys after
HSCT (M:4,5ys) with an overall survival(OS) of 80,3% at 5ys.
35pts survived more than 28 days and were evaluable for engraft-
ment. Three pts had no engraftment (all received UCB).One pt
died onD+34 with pulmonary aspergillosis and the other two under-
went a 2nd UCBT. One is alive and well 7 years after transplant.
Nine of 32 evaluable pts developed an acute-GVHD, grades II-IV
(grade III-IV: 2pts). Eight of 31 evaluable pts developed C-GVHD
(extensive in 3pts). There was no significant difference in OS in
the univariate or multivariate analysis in relation to age less than
or greater than 5 years (76% vs. 82%), type of donor, related or un-
related (87.5% vs. 75%), source of stem cells, bone marrow or cord
blood (91.7% vs. 70,8%), presence or absence of acute-GVHD (78%
vs 92%); or Chronic GVHD (75% vs 91%). Eight pts died between
21 to 1832 days post HSCT (M: 137 days), most deaths occurred
during the first year of transplant (6pts) and were related to viral in-
fections (4pts), fungal (1pt) and GVHD associated with bacterial in-
fections (3pts). The cumulative incidence of TRM at 100 days was
8% and at 1 year was of 17%. Chemotherapy was well tolerated,
but reactivation/acquisition of viral infections (mainly RSV) during
the period of neutropenia contributed to the early death in some pts.
Conclusions: Despite the small number of pts this experince shows
an excellent survival for pts transplanted for WAS. Infections com-
plications (viral or fungal) are frequent and must be detected quickly
and treated aggressively.74
EFFECTS OF BODY MASS INDEX (BMI) IN CHILDREN UNDERGOING AL-
LOGENEIC BONEMARROWTRANSPLANT (BMT) FOR HEMATOLOGIC MA-
LIGNANCIES
Aplenc, R.1, Pasquini, M.C.2, Zhang,M.-J.2, Zhu, X.2, McCarthy, P.L.3,
Ho, V.T.4, Cooke, K.R.5, Sung, L.6, Bunin, N.J.1 1Children’s Hospital of
Philadelphia; 2CIBMTR, Medical College of Wisconsin; 3Roswell Park
Cancer Institute; 4Dana-Farber Cancer Institute; 5University Hospitals
Case Medical Center; 6The Hospital for Sick Children
The rising incidence of pediatric obesity may significantly impact
BMT outcomes for malignant diseases, as has been demonstrated in
increased mortality in children undergoing BMT for aplastic ane-
mia. Obesity may influence chemotherapy dosing and transplant re-
lated mortality (TRM). We analyzed 3,687 children ages 2-18, who
received BMT for treatment of hematologic malignancies using ei-
ther busulfan/cyclophosphamide (BuCy, N 5 1,196) or Cy/total
body irradiation-based (CyTBI, N 5 2,495) conditioning, between
1990 and 2007. Recipients were classified according to age-adjusted
BMI percentiles as underweight (\5% [UW], n5 282), at risk of un-
derweight (6-25% [RUW], n 5 509), normal (26-75%,[NW] n 5
1469), at risk of overweight (76-95% [ROW], n 5 987) and obese
(.95%, [OB] n 5 444). Total doses of chemotherapy administered
to patients in the ROW and OB groups were divided by actual and
ideal body weight to estimate dose adjustment practices. Median
age (10-13 y) and race were similar in all groups; OB group had
higher number of patients with acute lymphocytic leukemia (58%),
with early disease (52%), unrelated donor recipients (56%) and
from a U.S. center (61%). The table below summarizes adjusted
probabilities according to BMI groups.Multivariate analysis demon-
strated a higher TRM in the OB group (RR 1.32, p 5 0.0075) com-
pared to NW. Conversely, patients in the OB group had decreased
risk of relapse (RR 0.72, p 5 0.0037) compared to NW. There was
no significant impact of UW and RUW compared to NW in any
outcomes, and no differences in relapse-free and overall survival ac-
cording to BMI groups. Chemotherapy adjustment assessment dem-
onstrated that among 1,061 patients with available dose information,
171 (16%) had probable dose adjustment for conditioning. Obesity
was associated with higher TRM and lower relapse in children
with hematologic malignancies, likely related to higher intensity
conditioning, as doses were most often calculated based on actualweight. Additionally, patients with low BMI experienced similar out-
comes compared to patients with NW.
Table.
Outcomes UW RUW NW ROW OB
@ 3 years (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) p-valueN 282 509 1467 986 443
TRM 18 (13-22) 19 (16-22) 21 (18-22) 22 (20-25) 28 (24-32) 0.0034
Relapse 33 (28-39) 33 (29-37) 29 (26-31) 25 (23-28) 21 (17-25) <0.0001
RFS 48 (42-54) 48 (44-53) 50 (48-53) 52 (49-56) 51 (47-56) 0.54
OS 55 (49-61) 57 (52-61) 58 (56-61) 58 (55-61) 56 (52-61) 0.81Abbreviations: CI, confidence interval; NW, normal weight; OB, obese;
OS, Overall Survival; RFS, relapse free survival; ROW, risk of over-
weight; RUW, risk of underweight; UW, underweight
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SINGLE CENTER EXPERIENCE OF THIOTEPA, TREOSULPHAN & FLUDAR-
ABINE BASED REGIMEN IN THALASSEMIA MAJOR
Choudhary, D.1, Katewa, S.2, Kharya, G.1, Anjan, M.1, Setia, R.1 1BLK
Super Speciality Hospital, New Delhi, Delhi, India; 2Hospital for Sick
Children, Toronto, ON, Canada
The only curative treatment for Thalassemia major (TM) is allo-
genic bone marrow transplantation. The most commonly used con-
ditioning regimen is Busulphan, Cyclophosphamide and Anti
thymocyte globulin. This has high regimen related toxicities
(RRT). To minimize RRT, especially in high risk TM we studied
new conditioning regimen in prospectivemanner. Between February
2010 - September 2011, seventeen children with b-Thalassemia ma-
jor underwent Allogenic Bone Marrow Transplant at BLK Super
Speciality Hospital. The median age was 12 years. (Range 2-16 yrs.).
There were nine males & eight females, four patients belonged to
Pesaro class II and 13 were class III. All patients received condition-
ing with Thiotepa 8 mg/kg on D -6, Treosulphan 14 gm/m2/day
from D-5 to D-3 & Fludarabine 40 mg/m2/day from D-5 to D -2.
Sixteen children were transplanted with bone marrow graft from
HLA identical siblings (6/6 antigen) and one patient received bone
marrow graft from mother (5/6 antigen). Mean cell doses given
were: 6.36 106 cells /kg BW for CD34+ cells (Range 2.06 – 14.02
 106/kg) and 7.84  10 8/kg /BW for mononuclear cells (Range
2.9- 17.5 108/kg). Two patients had ABO major mismatch, 4 had
minor mismatch and 1 had bidirectional mismatch. Cyclosporine
& Methotrexate was used as GVHD prophylaxis. No patient devel-
oped grade III - IVGVHD.None of them requiredTPNor parental
analgesia. Sixteen out of seventeen patients achieved donor engraft-
ment.Median neutrophil engraftment was achieved onD+15 (Range
11 – 17 day) and median platelet engraftment was achieved on D+21
(Range 9 to 34 days). One patient developed grade II gut GVHD.
One patient expired on D+6 due to neutropenic enterocolitis, sepsis
and intracranial hemorrhage.
Median follow-up period was 12 months (Range 1 -20 mo). Till
last follow up, all the patients who achieved engraftment are alive
and transfusion independent.
Conclusion: Thiotepa, Treosulphan & Fludarabine based regimen
has acceptable toxicities with stable donor engraftment.
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UNRELATED CORD BLOOD TRANSPLANT (UCBT) IS ASSOCIATED LOW
RATES OF LONGTERM, PERSISTENT GRAFT VERSUS HOST DISEASE
(GVHD)
Craddock, J.A., Alsultan, A., Quinones, R.R., Keating, A., Hild, E.,
Benkhalil, N., Law, D., Peltz, A., Nuechterlein, B., Drake, K.,
Smolik, S., Giller, R.H. Childrens Hospital Colorado/University of Colo-
rado School of Medicine, Aurora, CO
Reduced rates of acute and chronic GVHD make unrelated cord
blood an attractive stem cell source. Adult marrow and PBSC from
unrelated donors are associated with higher rates of GVHD, persis-
tence or progression of GVHDmanifestations, need for chronic im-
munosuppressive therapies, reduced quality of life, infection, organ
toxicities, and decreased overall survival (OS). In contrast, recent
analyses from our center and others have indicated that GVHD
following UCBT does not adversely impact OS (BMT 2011,
46:668-675). To better understand the longterm outcomes of
Oral Presentations S231GVHD in recipients of UCBT, we extended our analysis of patients
in our earlier study to determine rates of GVHDpersistence, contin-
ued immunosuppressive therapy, and survival at 1, 2 and 3 years
post-UCBT. A total of 81 patients were enrolled on our local,
IRB-approved UCBT trial between January 1996 and July 2007. Se-
venty-nine percent (54/68) of patients had malignant diagnoses and
21% (14/68) had nonmalignant disorders. Thirteen patients were ex-
cluded from analysis due to death prior to engraftment (7), graft re-
jection (4), or re-transplant during the follow-up period (2). Median
age of evaluable patients was 7.2 years (Range, 0.3-24.4years).
Among the 68 evaluable patients, 40 (59%) developed GVHD fol-
lowing UCBT. Based on Seattle criteria, 36 patients (53%) experi-
enced Grade I-IV acute GVHD with 17 (25%) classified as Grade
III-IV. Chronic GVH occurred in 21 of 58 patients (36%) surviving
beyond Day 100, including 4 with de novo chronic GVH. Chronic
GVHD was limited in 2 patients and extensive in 19. No new onset
chronic GVH was seen beyond 1 year post-transplant. In patients
with prior GVHD, persistent GVHD activity was present in 28%
(7/25), 14% (3/22) and 0% (0/20) of patients at 1, 2 and 3 years
post-UCBT. Among those with prior GVHD, 68% (17/25), 41%
(9/22) and 10% (2/20) of patients remained on one or more systemic
immunosuppressive medications at 1, 2 and 3 years post-UCBT.
Survival of patients with prior GVHD was 63% (25/40), 55% (22/
40) and 50% (20/40) at 1, 2 and 3 years post-UCBT. We conclude
that the course of GVHD following UCBT is both more manage-
able, i.e.-not associated with increased mortality, and resolves in
nearly all patients by 3 years post-UCBT allowing discontinuation
of immunosuppressive therapy. These features of GVHD in
UCBT appear to differentiate this product from adult unrelated
stem cell sources.
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ENCOURAGING RESULTS WITH THE USE OF FLUDARABINE BASED CON-
DITIONING REGIMENS IN CHILDRENWITH ACQUIRED AND CONGENITAL
BONE MARROW FAILURE SYNDROMES (BMFS)
George, B., Mathews, V., Ahmed, R., Abraham, A., Srivastava, A. Chris-
tian Medical College, Vellore, Tamilnadu, India
Between July 1999 and June 2011, sixty children (39 male and 21
female) with acquired and congenital BMFS underwent HLA iden-
tical stem cell transplantation (HSCT) using a fludarabine based
protocol. This included 39 patients with acquired aplastic anemia
(AA), 19 with Fanconi’s anemia (FA) and 2 with dyskeratosis conge-
nita (DKC). Three patients with FA hadmyelodysplastic syndromes.
The conditioning protocol used for AAwas Fludarabine (180mg/m2
over 6 days), Cyclophosphamide (120mg/kg over 2 days) + Anti- thy-
mocyte globulin (40mg/kg over 4 days). In patients with FA and
DKC, the dose of cyclophosphamide was reduced to 20 mg/kg and
in 3 patients with MDS, cyclophosphamide was replaced by busul-
fan. Cyclosporine with mini methotrexate was used for GVHD pro-
phylaxis. Graft source included peripheral blood stem cells (44) or
G-CSF stimulated bone marrow (16).
Fifty six patients engrafted (93.3%) while 2 patients with AA had
primary graft failure and 2 expired\2 weeks post HSCT. The me-
dian time to neutrophil engraftment was 14 days (range: 9 – 29) while
median time to platelet engraftment was 11 days (range: 7 – 31). Four
patients with FA/DKC and 2 patients with AA had secondary graft
rejection. Incidence of acute GVHD was 20% in children with AA
while it was 28.5% in children with congenital BFMS. Chronic
GVHD was seen in 33.3% of AA and 40% of children with congen-
ital BFMS. Three childrenwith AA and 3 with FA/DKChave under-
gone a second transplant using the same donor. The 2 year overall
survival is 83.3%with a survival of 87.1% in children with idiopathic
AA and 76.2% in children with congenital BFMS.
Fludarabine based protocols are associated with excellent survival
in children with acquired and congenital bone marrow failure syn-
dromes.
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OUTCOME OF MIXED CHIMERISM IN CHILDREN UNDERGOING ALLOGE-
NEIC STEM CELL TRANSPLANT (HSCT) FOR THALASSEMIA MAJOR
George, B., Mathews, V., Sindhuvi, E., Jain, S., Ahmed, R.,
Abraham, A., Srivastava, A. Christian Medical College, Vellore, Tamil-
nadu, IndiaA number of patients develop mixed chimerism following HSCT
for thalassemia despite the use of myeloablative chemotherapy. This
study analysed the outcome of mixed chimerism in children who un-
derwent allogeneic HSCT for thalassemia.
Between Jan 1995 to June 2011, 265 children underwent HLA
identical allogeneic HSCT for thalassemia using sibling or family
donors where chimerism data was available. Patients had chimerism
analysis performed using VNTRs performed initially at day 30 and
then as required. Mixed chimerism (MC) was graded as per Nesci
et al into level I (host cells\10%), level II (host cells 10-30%) or
level III (. 30%). Complete chimerism was the presence of\5%
host cells. Therapeutic interventions included taper of immunosup-
pression or use of donor lymphocyte infusion.
Seventy patients (26.4%) developed mixed chimerism either at
Day 30 or during subsequent follow up. Thirty five patients (50%)
had level I, 14 (20%) had level II and 8 (11.4%) had level III MC
while 13 (18.6%) had complete chimerism (CC) on day 30 but sub-
sequently developed MC. Of the 35 patients with Level 1 MC, 14
achieved CC while 17 (70%) had stable mixed chimerism (3 re-
mained at level 1; 4 progressed to level II or III) and 4 (11.4%) re-
jected. Of the 14 with Level 1I MC, 2 (14.2%) achieved CC, 6
(42.8%) had stable mixed chimerism with transfusion independence
and 6 (42.8%) rejected. Among 8 patients with level III chimerism, 6
(75%) rejected while 1 achieved CC after a DLI and 1 remained at
level III but remained transfusion independent. Thirteen patients
achieved CC by Day +30 but subsequently lost their chimerism - 2
dropped to level I, 5 to level II, 6 to level III. Of these, 11 (84.6%)
are either in CC or have stable mixed chimerism while 2 (15.4%)
had secondary rejection.
There is an increased risk of secondary rejection in patients with
level II and III MC at Day 30 following allogeneic HSCT for thal-
assemia. Newer strategies need to be adopted to reduce graft rejec-
tion in these patients.
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PATIENTS WITH EARLY INITIATION OF DLI FOR MIXED DONOR CHIME-
RISM WERE MORE LIKELY TO HAVE IMPROVEMENT IN DONOR CHIME-
RISM
Haines, H.L.1, Filipovich, A.H.2 1University of Alabama Birmingham,
Birmingham, AL; 2Cincinnati Children’s Hospital Medical Center, Cin-
cinnati, OH
Background: Increased use of reduced intensity conditioning regi-
mens in the pediatric setting mean more patients will require T
cell donor lymphocyte infusion (DLI) for mixed donor chimerism.
A retrospective review of 33 patients (age # 21 years) who received
DLI as primary cellular therapy for mixed chimerism from 2006 to
2010 was conducted.
Patients andmethods:Most patients underwent hematopoietic cell
transplant (HCT) for non-malignant disease after a preparative reg-
imen consisting of alemtuzumab, fludarabine andmelphalan. Indica-
tions for HCT were immune deficiency (29), Fanconi Anemia (1),
Hurler’s (1), Langerhans Cell Histiocytosis (1), and myelodysplasia
(1). Patients received DLI for mixed chimerism after reduction in
immune suppression was ineffective.
Results: Patients received a mean of 3.2 DLIs (range 1-12). Mean
first T cell dose was 2.6 X 106 cells/kg; mean total T cell dose was
5.8 X 107 cells/kg. Average donor chimerism prior to first DLI was
42%. Sixteen patients (48%) had increase from pre-DLI donor chi-
merism of $ 20% within eight weeks of DLI and were classified as
responders. Response was seen at a mean of 21 days after DLI (range
1-42) with peak donor chimerism seen at 51 days. Complete response
(peak donor chimerism of .99%) was seen in eleven patients. One
patient had graft versus host disease (GVHD) prior to DLI. Ten pa-
tients, all responders, developedGVHDafterDLI. GVHDwas gen-
erally mild with only two patients having $ grade 3.
When responders were compared with non-responders (Table 1)
there was no difference in donor chimerism prior to DLI therapy,
number of DLIs, or total and initial T cell doses. However, re-
sponders received their first DLI earlier after HCT, likely due to re-
sponders’ tendency toward earlier loss of donor chimerism after
HCT and shorter lag time between decreased donor chimerism
and first DLI. Response rates were higher for patients who received
DLI early after donor chimerism drop. Patients who received first
DLI # 50 days after loss of donor chimerism (N 5 17) had a 71%
response rate; patients who received DLI . 50 days (N 5 13) after
